A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination With AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
Latest Information Update: 13 Oct 2023
At a glance
- Drugs Tarlatamab (Primary) ; Zeluvalimab (Primary)
- Indications Brain metastases; Small cell lung cancer
- Focus Adverse reactions
- Acronyms DeLLphi-302
- Sponsors Amgen
- 10 Oct 2023 Planned End Date changed from 15 Jan 2026 to 11 Jan 2025.
- 18 Jul 2023 Planned End Date changed from 27 Aug 2025 to 15 Jan 2026.
- 18 Jul 2023 Planned primary completion date changed from 12 Jul 2023 to 23 Aug 2023.